

+ DE LA
COMUNIDAD DE
SAN YSIDRO



**SAN YSIDRO
HEALTH**

Celebrating 55 Years

*Of Improving Health & Well-Being
With Access For All*

Diabetic Retinopathy Screening Point-of-Care Artificial Intelligence (DRES-POCAI)

NCQA Health Innovation Summit 2025

DRES-POCAI: Experienced Leadership Committed to Health Equity



Sonia Tucker – Vice President of Population Health

- ❖ Leads population health initiatives, inclusive of quality of care, risk management, patient access and experience, etc.
- ❖ Currently serves as the Co-Principal Investigator for DRES-POCAI's research phase



Edgar Diaz – Director, Research and Health Promotion

- ❖ Extensive background in leading the implementation of large multidisciplinary and collaborative research projects
- ❖ Currently serves as Co-Investigator of DRES-POCAI's research phase

San Ysidro Health & DRES-POCAI: Transforming Diabetes Care Access

San Ysidro Health:

A leading Federally Qualified Health Center (FQHC) providing medical, dental, and behavioral health services to over 160k diverse, underserved patients in San Diego County for more than 55 years.

DRES-POCAI:

A transformative, innovative, and sustainable Artificial Intelligence - Diabetic Retinopathy screening service delivered within the primary care setting to advance access to care for patients at community health centers.

OUR COLLECTIVE IMPACT



160,000 +
lives served



3,000 +
workforce
advancing
our mission



26
health centers




**DIABETIC RETINAL
SCREENING**



**SAN YSIDRO
HEALTH**

San Ysidro Health & DRES-POCAI: Transforming Diabetes Care Access

A man in a tan coat and cap is walking on a sidewalk, using a white cane. The background is a blurred city street.

Diabetic retinopathy is a serious eye condition caused by damage to the blood vessels in the retina, the light-sensitive tissue at the back of the eye, due to diabetes. **It is the leading cause of vision loss and blindness in working-age adults.** Early detection and treatment can significantly reduce the risk of vision loss.

Stages of Progression

More-than-Mild Diabetic Retinopathy:

This is the early stage where blood vessels in the retina weaken and may leak fluid or blood, dot-and-blot hemorrhages; cotton-wool spots and hard exudates may be present.

Vision Threatening Diabetic Retinopathy:

This is a more advanced stage where swelling of the central part of the retina responsible for sharp, detailed vision and new, abnormal blood vessels grow on the retina. These new vessels are fragile and can bleed easily, leading to vision loss.

***“I am going blind,
so I always stop
to look at the sky”***

Bob LaMeres, 69
Vision threatening diabetic
Retinopathy diagnosis




Diabetic Retinopathy Disproportionally Impacts Communities Served by FQHCs

- Leading cause of preventable blindness, costing **Over \$70 Billion annually**.
- Affects **9.6 million people** in the U.S.
- Deep inequity as it **affects underserved communities most**.
- Only 35% of San Ysidro Health patients (low-income, diverse) complete timely screenings due to social determinants of health.
- Current **referral system creates access barriers** (time, insurance, cost, transportation, navigation).
- Significantly **impacts quality of life**, affecting daily activities, social interactions, and overall well-being.

DRES-POCAI: System Transformation for Equitable Eye Care

- **Solution:** Integrate Artificial Intelligence (AI) -Diabetic Retinopathy screening directly into the primary care setting
“Right Care, Right Time, Right Place”.
- **Immediate Impact:** Accurate results & risk stratification in minutes.
- **Transforms Care:** Eliminates barriers to access, enables timely diagnosis, appropriate referral, and treatment. Empowers providers and patients by providing tools to manage their condition.

DRES-POCAI: Use of AI Technology for Risk Stratification



Better Patient Outcomes:

Supports clinical decision-making, early diagnosis & timely treatment

Optimization of Limited Health Resources:

Referrals to eye specialists only when needed


Immediate Results at the Point-of-Care

Actionable results immediately after the test

Diabetic Retinopathy Screening Equipment

Using Topcon NW400 camera


ART-QGFP-TOP-20230926



The eye being imaged can be changed by selecting the "OD (R)" and "OS (L)" buttons to switch to the right and left eye respectively. The fixation can be changed by selecting "D" (Optic Disc), "C" (Central) or "M" (Macula) in the fixation selector button.

Press "OD (R)" and "OS (L)" buttons to switch to the right and left eye respectively


(a) Right Eye Optic Disc Centered



Switch to Optic Disc centered images by selecting 'D'

Switch to Macula centered images by selecting 'M'

(b) Left Eye Optic Disc Centered




Switch to Optic Disc centered images by selecting 'D'

Switch to Macula centered images by selecting 'M'



Eye Anatomy and 2-Field Imaging

ART-QGFP-TOP-20230926



RIGHT EYE

LEFT EYE




AIM-HI

Augmented Intelligence in
Medicine and Healthcare Initiative

Diabetic Retinopathy Screening Equipment



Solution Integration within EHR



DRES-POCAI: Integration into SYH EHR – Pre-screening Process

1 - In an encounter, order the EyeArt Diabetic Retinopathy Exam in the Visit Taskbar

2 - Procedure will appear in Oder Shopping Cart

3 - Association of proper diagnosis to procedure

Test Ammy
Male, 16 y.o., 3/21/2007
MRN: 10000784
SDP: No Value Set
Scheduled
Code: Assume Full (no ACP docs)

COVID-19 Vaccine: Unknown
Isolation: None
Care Team: No PCP
Coverage: None
Allergies: Not on File
2/15 ORDERS ONLY
No vital signs recorded for this encounter.

LAST 3YR
No visits
Other (1) *

PROBLEM LIST (0)

SOCIAL DETERMINANTS

Med Management SmartSets BestPractice

Medication Management

Patient-Reported

Name Dose, Frequency Adh

Outpatient Procedures Ordered This Visit

EyeArt Diabetic Retinopathy Exam

EyeArt Diabetic Retinopathy Exam

EyeArt Diabetic Retinopathy Exam

Mark as Reviewed Never Reviewed

Click here to select a pharmacy

Associate Signed Orders Patient Estimate Providers Current Interactions

SmartSets

Search for new SmartSet Add

BestPractice Advisories

Important (1)

This patient is at a high risk for CHD and has not had an LDL-C test completed in the last year. Place an order for an LDL-C test.

Open SmartSet

Suggestion (1)

This patient has a diagnosis of diabetes and has not had a hemoglobin A1C test in the past 3 months. Consider completing the recommended SmartSet.

Last HGBA1C: Not on file

Open SmartSet Do Not Open Hemoglobin A1C Preview

Acknowledge Reason

Low risk Refused

EyeArt Diabetic Retinopathy Exam - type: Ophth, code: EYNK-EA-US-DRO

eyeart ADD DX (2)

Dx Association Edit Multiple Estimate Options

Outpatient

EyeArt Diabetic Retinopathy Exam

Routine, Clinic Performed

Select a pharmacy

3 PEND SIGN ORDERS (1)

Associate Diagnoses

Ammy, Test

Search for diagnosis Add Common

Other specified diabetes mellitus with diabete...

Diabetic retinopathy screening

EyeArt Diabetic Retinopathy Exam

Accept Cancel

DRES-POCAI: Integration into SYH EHR – Pre-screening Process

4 - In Chart Review

5 - The authorizing provider will receive a result In-Basket message to review the results

6 - Automated referral process – Urgent or STAT according to the results.

The "View Image" hyperlink will open the attached result PDF in a popup window

The screenshot shows the 'Chart Review' tab in the EHR system. Under the 'Recent' section, there is a table listing recent exams. The first entry is an 'EyeArt Diabetic Retinopathy Exam' performed yesterday (02/21/2024) by a physician. Below this, the details of the exam are shown, including the component 'EYEART EXAM RESULT SUMMARY' and the result 'Vision-threatening DR detected (ETDRS level 53 or higher and/or macular edema) in both eyes. Refer to an eye care professional for evaluation (with preferential scheduling if possible)'. The result is marked as 'Positive!'. There is a 'View Image' hyperlink in the 'Linked Documents' section, which is highlighted by a blue box and an arrow pointing to it from the text on the left.

The screenshot shows the 'In-Basket' interface. It displays a list of messages, including a result message for an 'EyeArt Diabetic Retinopathy Exam'. The message is marked as 'Read' and 'New'. The details of the exam are shown, including the component 'EYEART EXAM RESULT SUMMARY' and the result 'Vision-threatening DR detected (ETDRS level 53 or higher and/or macular edema) in both eyes. Refer to an eye care professional for evaluation (with preferential scheduling if possible)'. The result is marked as 'Positive!'. There is a 'View Image' hyperlink in the 'Linked Documents' section, which is highlighted by a blue box and an arrow pointing to it from the text on the left.

The screenshot shows a popup window displaying the 'EyeArt Diabetic Retinopathy Exam' result PDF. The PDF contains the same information as the EHR interface, including the component 'EYEART EXAM RESULT SUMMARY' and the result 'Vision-threatening DR detected (ETDRS level 53 or higher and/or macular edema) in both eyes. Refer to an eye care professional for evaluation (with preferential scheduling if possible)'. The result is marked as 'Positive!'. There is a 'View Image' hyperlink in the 'Linked Documents' section, which is highlighted by a blue box and an arrow pointing to it from the text on the left.

DRES-POCAI: Systems Transformation in Primary Care

Screening Results in Minutes

- Uses AI technology approved by the Food & Drug Administration to detect more than mild & vision-threatening retinopathy providing immediate results at the Point-of-Care

Intelligent Interaction with the Electronic Health Record System

- AI generated results are automatically documented in the Electronic Health Record system, trigger risk-based stratified referrals, and prompts provider for review & approval (True Systems Transformation)

Leading FQHC Innovation

- Unique integrated system designed to improve quality of care for people with diabetes
- First FQHC in the West Coast to provide AI-Diabetic Retinopathy Screenings
- System integration developed in-house for San Ysidro Health, a precedent setting innovation that is *first of its kind*

DRES-POCAI: Phased Execution for Scalable, Sustainable Impact

Research phase

Operational Phase

ROADMAP

METRICS

INTERNAL RESEARCH PHASE (2024-2025)

Assessed the benefits and efficiency of point-of-care diabetic retinopathy screenings

Increased Screening Rates by ~30% in Enrolled Participants

QUALITY IMPROVEMENT PHASE (2026-2027)

Optimize clinical implementation, establish workflows & test billing processes and reimbursement rates

Workflow Efficiency
Revenue vs. Cost & Payer Engagement Progress

SUSTAINABILITY PHASE (2026 & Beyond)

Negotiation to maximize revenue from health plans for AI-powered screenings

Improved Reimbursement Rates & Outcome-Based Incentives



**SAN YSIDRO
HEALTH**

Service Roadmap & Metrics

DRES-POCAI (Research Phase): Recruitment and Data Collection


DRES-POCAI Aims to evaluate the implementation and effectiveness of a multicomponent AI Clinical Intervention using a patient-level randomized controlled clinical trial.

Inclusion criteria: SYH patients with DM who have not had a retinal exam in the last 11 months and:

- 1) Established and active patients of SYH-CV and KC (having had a medical appointment in the last 18 months);
- 2) 22 years of age or older;
- 3) Medical appointment scheduled during the intervention period.

Exclusion criteria:

- 1) Have a prior diagnosis of DR, macular edema, or retinal vascular occlusion;
- 2) Have persistent visual Impairment in one or both eyes;
- 3) History of ocular injections, laser treatment of the retina, or intraocular surgery (excluding cataract surgery);
- 4) Diagnosis of mental or degenerative disease that prevents self-consent for the study.



SYH-Chula Vista



**SYH-King Chavez
Intervention Sites**



SYH-Ocean View

DRES-POCAI: The Team



Fatima Munoz, MD, MPH

Associate VP Health Support Services



Sonia Tucker, MD, MBA

VP Population Health




Edgar Diaz, MD

Director of Research



Sharon Velasquez, MD

Associate Chief Medical Officer



Oliver Solis, OD

SYHC Optometrist



Brian Snook, DO

Associate Chief Medical Officer



Research Evaluation Partner



AI Partner and Subject Matter Expert



Nicole Stadnick, PhD, MPH

Associate Professor



Marva Seifert, PhD

Assistant Professor



Chaithanya Ramachandra, PhD

Head of R&D



Malavika Bhaskaranand, PhD

Head of Product Management



Sandeep Bhat, PhD

Head of Engineering



AIM-HI

Augmented Intelligence in
Medicine and Healthcare Initiative

Research Partnership

DRES-POCAI SYHealth Research: Co-Designed Implementation Process

Stakeholder Engagement

7 focus groups as part of the Community Co-Design Phase

- 73% patient/staff solutions adopted in research phase
- 19% of solutions were flagged for future adoption in operational phase

Preliminary Data

70% of patients completed diabetic retinopathy screening in AI group

34% of patients completed screening with standard care (referral to eye doctor)

AI Acceptance

90% of patients recommend AI diabetic retinopathy screening to friends and family

DRES-POCAI: Sustainable Model for Long-Term Impact

Phase 1: Generate revenue via billable **PREVENTIVE PRIMARY CARE VISITS** for patients with diabetes that include AI-screening

Phase 2: Use Phase 1 data to secure **ENHANCED PAYER REIMBURSEMENT & INCENTIVES** for long-term sustainability
(Increased screenings + improved outcomes)



DRES-POCAI: Leveraging Existing Infrastructure for Targeted Reach




Patient Identification: Use data to proactively identify & engage San Ysidro Health's unscreened diabetic patients.



Phased Expansion: Establishing services at 3 high-volume clinics across San Ysidro Health's network.



Mobile Clinics: Utilize mobile clinics to reach rural and small volume clinics and other underserved communities.



Implementation Considerations:

1. Data Readiness & Infrastructure
2. AI Models must be trained in diverse, representative datasets
3. Staff Training on AI Tools and Implementation of change management strategies to improve buy in.
4. Cost and Funding: Partnership, grants, and focus on areas that improve efficacy and patient outcomes.
5. Solution must be HIPAA compliant.
6. Ensure transparency on how the AI solution works.

Opportunities Considerations:

1. Clinical Decision Support – DRES-POCAI is a great example.
2. Operational Efficiency
3. Population Health Management
4. Predictive Analytics

Summary: You should assess Readiness, Start small, engage patients and providers, and measure impact.

DRES-POCAI: Preserving Vision and Empowering Lives

Ultimately, **DRES-POCAI is about more than AI and efficient workflows.** It's about **preventing blindness and enhancing lives** in the communities we serve

By bringing accessible, efficient AI screening directly into the primary care setting, we replace months of waiting and uncertainty with immediate, actionable results. This means early detection of diabetic retinopathy, often before symptoms appear, allowing for timely treatment that **can prevent irreversible blindness**

Imagine the Impact

Individuals maintaining their independence, continuing to work, and engaging fully with their families and communities. This isn't just about improving health outcomes; it's about upholding dignity, reducing the profound personal and family burden of vision loss, and lowering long-term healthcare costs



Seeing the World with
Normal Vision



Seeing the World with
Diabetic Retinopathy

DRES-POCAI: Contact Information

Dr. Edgar Diaz

Director, Research & Health Promotion
edgar.diaz@syhealth.org


Dr. Fatima Muñoz

Associate VP, Health Support Services
fatima.munoz@syhealth.org

Dr. Sonia Tucker

VP, Population Health
sonia.tucker@syhealth.org

Thank you



Contact Information